Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

DYANAVEL XR 5 MG TABLET

amphetamine
$7.8495per EA
DEA Schedule CII

Strength

5 mg/1

Manufacturer

NextWave Pharmaceuticals, Inc

NDC

24478010601

Classification

Brand

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Last Updated

1/1/2026

Active Ingredients

AMPHETAMINE

Approval Type

New Drug (NDA)

FDA Application

NDA210526

On Market Since

11/4/2021

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+2.0%

1Y

+1.8%

3Y

N/A

5Y

N/A

All

+9.6%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

EXCEDRIN EXTRA STRENGTH GELTAB
Brand
00067202124•Haleon US Holdings LLC
$0.1205
per EA
EXCEDRIN EXTRA STRENGTH CAPLET
Brand
00067200020•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN EXTRA STRENGTH CAPLET
Brand
00067200024•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN EXTRA STRENGTH CAPLET
Brand
00067200033•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN EXTRA STRENGTH CAPLET
Brand
00067200050•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN EXTRA STRENGTH CAPLET
Brand
00067200077•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN EXTRA STRENGTH CAPLET
Brand
00067200091•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN MIGRAINE GELTAB
Brand
00067203520•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN MIGRAINE CAPLET
Brand
00067203924•Haleon US Holdings LLC
$0.1338
per EA
EXCEDRIN MIGRAINE CAPLET
Brand
00067203933•Haleon US Holdings LLC
$0.1338
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy